INSTITUTIONAL PRESENTATION
2Q22
Disclaimer
The material that follows is a presentation of general background information about RaiaDrogasil S.A. (the "Company") as of the date of the presentation. It is information in summary form and does not purport to be complete. It is not intended to be relied upon as advice to potential investors. This presentation is strictly confidential and may not be disclosed to any other person. No representation or warranty, express or implied, is made concerning, and no reliance should be placed on, the accuracy, fairness, or completeness of the information presented herein.
This presentation contains statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Exchange Act of 1934. Such forward-looking statements are only predictions and are not guarantees of future performance. Investors are cautioned that any such forward-looking statements are and will be, as the case may be, subject to many risks, uncertainties and factors relating to the operations and business environments of the Company that may cause the actual results of the companies to be materially different from any future results expressed or implied in such forward-looking statements.
Although the Company believes that the expectations and assumptions reflected in the forward-looking statements are reasonable based on information currently available to the Company's management, the Company cannot guarantee future results or events. The Company expressly disclaims a duty to update any of the forward looking-statements.
Our securities have not been and will not be registered under the Securities Act or under any state securities laws in the United States, and are being offered under exemptions from registration under the Securities Act. Securities may not be offered or sold in the United States unless they are registered or exempt from registration under the Securities Act. Any offering to be made in the United States will be made by means of an offering circular that may be obtained from the agents.
This presentation does not constitute an offer, or invitation, or solicitation of an offer, to subscribe for or purchase any securities. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever.
2
Leading the consolidation of pharma retailing in Brazil.
Our Purpose: | +200 years |
of combined history of Raia and | |
Drogasil, merged in 2011 |
#1 Pharmacy
chain in Brazil
Taking close care of people's health and well-being during all times of their lives
2,581
pharmacies across every Brazilian state
45 million
unique active customers (2Q22 LTM)
307 million
tickets (2Q22 LTM)
R$ 28.0 billion
Gross revenue (2Q22 LTM, R$) +19% Y/Y growth
R$ 2.0 billion
EBITDA (2Q22 LTM) +15% Y/Y growth
260
new pharmacies in 2022 and 980 until 2025 (guidance)
NPS 90
net promoter score
500 million
digital sessions (annualized)
14.4%
market share in the 2Q22
AAA(bra)
rating by Fitch
3
Fragmented market with secular demand growth due to the ageing of the population.
Faster population ageing
(# of years for the population over 65 to grow from 7% to 14%. Source: The World Bank.)
Brazil (2011 - 2032) | 21 | |
China (2000 - 2026) | 26 | |
Japan (1970 - 1996) | 26 | |
Spain (1947 - 1992) | 45 | |
UK (1930 - 1975) | 45 | |
Canada (1944 | - 2009) | 65 |
USA (1944 | - 2013) | 69 |
Australia (1938 -2011) | 73 | |
Sweden (1890 | - 1975) | 85 |
France (1865 | - 1980) | 115 |
Pharmaceutical market should maintain
accelerated growth in the long term
(R$ billions. Source: IQVIA.) | 144 |
126
85 | 96 103113 | ||||||||||||||||||||
43 | 50 | 58 | 66 | 75 | |||||||||||||||||
11 | 12 | 13 | 15 | 17 | 19 | 21 | 21 | 25 | 30 | 36 | |||||||||||
2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
Population over 65 years
(Millions. Source: IBGE.)
40.1 | ||||
30.0 | ||||
20.0 | ||||
9.7 | 13.3 | |||
2000 | 2010 | 2020 | 2030 | 2040 |
Fragmented market: opportunity for consolidation
(Market share. Source: IQVIA.)
9.2% | 9.8% | 10.8% | 11.4% | 11.8% | 13.4% | 13.5% | 14.1% | ||||||||
18.6% | 17.5% | 16.3% | 16.4% | 16.3% | 16.0% | 15.2% | 15.2% | ||||||||
22.5% | 24.7% | 24.9% | 23.9% | 23.3% | 22.3% | 21.8% | 21.0% | ||||||||
17.2% | 15.9% | 16.7% | 17.6% | 18.4% | 19.1% | 20.2% | 22.0% | ||||||||
32.5% | 32.1% | 31.3% | 30.7% | 30.3% | 29.1% | 29.2% | 27.6% | ||||||||
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | ||||||||
Independents | Assoc./Franch. | Other Chains | Abrafarma #2 to 5 | RD | |||||||||||
4
RD completed 10 years of history, with strong growth and value creation based on a traditional retail strategy.
776 864
Pharmacies
(Store count)
3x
2,490
2,299
2,070
1,822
1,607
1,417
1,232
1,091
967
Employees
(Thousands)
3x
50.6
44.6
41.5
36.5
32.3
28.9
26.5
23.7
20.121.5
17.2
4.7 5.6
Gross revenue
(R$ billions)
5x
25.6
21.2
18.4
15.5
13.9
11.8
9.4
7.8
6.5
Adjusted EBITDA
(R$ millions)
7x
1,807
1,429
1,344
1,195
1,130
988
744
544
326 357
272
'11 | '12 | '13 | '14 | '15 | '16 | '17 | '18 | '19 | '20 | '21 | '11 | '12 | '13 | '14 | '15 | '16 | '17 | '18 | '19 | '20 | '21 | '11 | '12 | '13 | '14 | '15 | '16 | '17 | '18 | '19 | '20 | '21 | '11 | '12 | '13 | '14 | '15 | '16 | '17 | '18 | '19 | '20 | '21 |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Raia Drogasil SA published this content on 28 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2022 13:39:07 UTC.